Phase 1/2 pilot study of methotrexate-laurocapram topical gel for the treatment of patients with early-stage mycosis fungoides

Objectives: To assess the safety and tolerability of a topical gel formulation combining methotrexate and laurocapram and to obtain preliminary information on the therapeutic potential of methortrexate-laurocapram in patients with early-stage mycosis fungoides (stage IA or IB). Design: An open-label, phase 1/2 pilot study Setting: Two academic referral centers. Patients: Ten patients 18 years or older with histologically confirmed stage IA or IB mycosis fungoides. Intervention: The gel formulation of methotrekate-laurocapram was applied to the total body surface, excluding genital, perianal areas, nipples, face, and skin under the breasts, on an every-other-day basis for 24 consecutive weeks. Main Outcome Measures: The safety of methotrexate-laurocapram was assessed in this study by reviewing adverse events and laboratory data. Efficacy outcomes ineluded changes in lesion condition and severity assessments, reduction in area of sample lesions, and the investigator's global evaluation. Results: Adverse events consisted of skin reactions of mild severity. No clinically significant laboratory abnormalities were observed. Based on the investigator's global evaluation at the end of the treatment phase (week 24), 7 (78%) of 9 patients demonstrated a slight-to-moderate response to treatment with methotrexate-laurocapram. Statistical significance (P=.049) was reached for induration and pruritus, a trend (P=.10) was observed for erythema, and no change was found for scaling (P=.37). Conclusions: These findings indicate that the topical administration of methotrexate-laurocapram is safe and in general well tolerated. This treatment may represent a new therapeutic potential for patients with mycosis fungoides.